Maternal Coronavirus Infections and Neonates Born to Mothers with SARS-CoV-2: A Systematic Review

Waldemar Naves do Amaral 1, Carolina Leão de Moraes 1, Ana Paula dos Santos Rodrigues 1, Matias Noll 2, Jalsi Tacon Arruda 3 and Carolina Rodrigues Mendonça 1, *

1 Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal de Goiás, 74605-050 Goiânia, Brazil; waldemar@sbus.org.br (W.N.d.A.); carolina.leao.moraes2@gmail.com (C.L.d.M.); anapsr@gmail.com (A.P.d.S.R.)
2 Instituto Federal Goiano, Campus Ceres, 76300-000 Ceres, Brazil; matias.noll@ifgoiano.edu.br
3 Departamento de Medicina, Centro Universitário de Anápolis—Univangélica, 75083-515 Anápolis, Brazil; jalsitacon@gmail.com
* Correspondence: carol_mendonca85@hotmail.com

Received: 28 October 2020; Accepted: 16 November 2020; Published: 24 November 2020

Abstract: The coronavirus disease 2019 (COVID-19) pandemic is continuously affecting the lives of all people. Understanding the impact of COVID-19 on pregnancy in terms of morbidity, mortality, and perinatal maternal and fetal outcomes is essential to propose strategies for prevention and infection control. Here, we conducted a systematic review to investigate pregnant women infected with COVID-19 in terms of signs and symptoms, type of delivery, comorbidities, maternal and neonatal outcomes, and the possibility of vertical transmission. A search on Embase and PubMed databases was performed on 31 October 2020. Observational studies and case reports on pregnant women infected with COVID-19 were included without language restrictions. The 70 selected studies included a total of 1457 pregnant women diagnosed with COVID-19 in the first, second, and third trimesters of pregnancy. The most common signs and symptoms were fever, cough, and nausea. The most frequent comorbidities were obesity, hypertensive disorders, and gestational diabetes. Among maternal and fetal outcomes, premature birth (n = 64), maternal death (n = 15), intrauterine fetal death or neonatal death (n = 16), cases of intrauterine fetal distress (n = 28), miscarriage (n = 7), decreased fetal movements (n = 19), and severe neonatal asphyxia (n = 5) were the most frequent. Thirty-nine newborns tested positive for SARS-CoV-2. Additionally, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in the placenta (n = 13) and breast milk (n = 6). This review indicates that COVID-19 during pregnancy can result in maternal, fetal, and neonatal complications. In addition, SARS-CoV-2 viral exposure of neonates during pregnancy and delivery cannot be ruled out. Thus, we highlight the need for long-term follow-up of newborns from mothers diagnosed with COVID-19 to establish the full implications of SARS-CoV-2 infection in these children.

Keywords: pregnant woman; coronavirus; infectious disease transmission; vertical transmission; obstetric management; SARS-CoV-2; systematic review

1. Introduction

Coronavirus disease 2019 (COVID-19) is an infectious condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first reported in December 2019 after an outbreak of pneumonia of unknown etiology was identified in Wuhan, China [1,2]. Currently, the virus continues to spread to different regions of the world, including several countries in Europe and the United States, which reported the highest number of confirmed cases and deaths in March and April [2].
With continuous emergence of new data, there is an increasing understanding of the mechanisms of the disease [3]. Although studies about the effects of COVID-19 on pregnancy are expanding, there are still many unanswered questions [4,5]. Data regarding COVID-19 and its effects on both mother and fetus or newborn are still scarce, and the potential risk of vertical transmission is a major concern [6]. It is well established that pregnant women, in general, are vulnerable to infections; therefore, both pregnant women and newborns should be considered at risk for COVID-19 [6,7]. Thus, it is important to understand the impact of COVID-19 on pregnant women [6] in terms of morbidity, mortality, and perinatal maternal and fetal outcomes [7] to propose strategies for prevention and infection control [6].

Systematic reviews on the topic have already been published [10–13] and indicated that neonatal COVID-19 infection is low, and uncommonly symptomatic. As COVID-19 infection is growing in different cities around the world, new research is being published all the time. In this sense, a broad and current research on the maternal clinical characteristics of the COVID-19 infection and the neonatal results, during childbirth or postnatal (by environmental exposure), can provide important new information to guide clinical and preventive practice guidelines. Therefore, we aimed to investigate pregnant women infected with COVID-19 in terms of signs and symptoms, type of delivery, comorbidities, clinical outcomes (maternal and neonatal), and possibility of vertical transmission (via placenta or hematogenous route, birth canal, and lactation) through a systematic review. We believe that these findings will make a significant contribution to the current clinical and preventive practice guidelines worldwide.

2. Materials and Methods

A systematic review on pregnancy and COVID-19 was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [14] guideline. Our study was conducted in six stages: (1) Formulation of the study question, (2) elaboration of inclusion and exclusion criteria, (3) definition of the information to be extracted from the identified and selected articles, (4) analysis, (5) interpretation of results, and (6) presentation of the review [15]. The protocol was registered with PROSPERO (CRD42020220263).

2.1. Information Sources and Search Strategy

An electronic search was performed in Embase and PubMed databases for articles published until 31 October 2020. The reference lists of selected articles and information available on Google Scholar were also searched. The following keywords were used for the searches: Pregnancy, pregnant woman, pregnant women, COVID-19, SARS-CoV-2, and vertical transmission. Operator fields were filled out with AND/OR. We used the following terms to search in PubMed: ((Pregnancy) OR (pregnant woman) OR (pregnant women)) AND ((COVID-19) OR (SARS-CoV-2) OR (coronavirus pregnancy) AND (vertical transmission)).

2.2. Eligibility Criteria

The inclusion criteria were as follows: (1) Outpatient or population-based observational studies (prospective or retrospective) or case reports and pre-print articles (2) in any language, (3) published between December 2019 and October 2020; (4) studies with pregnant women with laboratory diagnosis for COVID-19; and (5) pregnant women in any gestational trimester. Letters to the editor, opinions, comments, correspondence articles reporting previously published data, reviews, guidelines, and duplicate studies (i.e., found in more than one database) were excluded.

2.3. Data Extraction and Quality Assessment

Titles and abstracts were used to screen for potentially eligible studies. The identified studies were then read in full and critically evaluated by three members of the research team (C.R.M., C.L.M., and J.T.A.) (Figure 1) based on their knowledge on pregnancy and COVID-19. Doubts and/or
disagreements about the articles were discussed by the research team to make a consensus decision. The data extracted from the studies were as follows: (1) Signs and symptoms of the mother and fetus, (2) gestational age and pregnancy results (maternal or fetal death), (3) type of delivery (natural, emergency or elective cesarean section, abortion, or complications), and (4) possibility of SARS-CoV-2 vertical transmission.

The quality of the studies was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) [16,17]. The quality of the evidence from the studies was classified into four categories: High, moderate, low, or very low [16,17].

3. Results

A flow diagram based on the PRISMA guideline was created to represent the different stages of article selection (Figure 1).

3.1. Study Selection

From the 1720 studies retrieved, 1708 were identified in Embase and PubMed while 12 were taken from other sources. After exclusion of duplicate studies, a total of 1035 titles and abstracts were collected. Among these, 218 manuscripts were retrieved for full reading by the three authors (C.R.M., C.L.M., and J.T.A.) independently. A total of 70 studies met the inclusion criteria [5,7,9,18–85]. The main findings of the selected studies are shown in Table 1.
Table 1. Data on signs and symptoms, gestational age, type of delivery, comorbidity, and vertical transmission of coronavirus disease 2019 (COVID-19) in pregnant women.

| First Author, Year, and Country | Study Size and Age | Study Design | Signs and Symptoms | Gestational Age | Type of Delivery and Maternal or Fetal Complications | GRADE * |
|---------------------------------|-------------------|-------------|--------------------|----------------|-----------------------------------------------------|---------|
| Algarroba, et al., 2020 [85] EUA | n = 1 Age: 40 years | Case report  | Worsering shortness of breath, cough, and hypoxia | NR             | Third trimester (28 weeks gestational age) | Cesarean delivery (n = 1) | •••○○ |
| Alzamora et al., 2020 [18] Peru | n = 1 Age: 41 years | Case report  | General malaise, fatigue, and low-grade fever | NR             | Third trimester (33 weeks gestational age) | Emergency cesarean section (n = 1) | •○○○ |
| Algarroba, et al., 2020 [85] Peru | n = 1 Age: 28 years | Case report  | Fever (39.2°C), myalgia, fatigue, mild pain with swallowing, diarrhea, and dry cough for 2 days | NR             | Second trimester (19 weeks gestational age) | Vaginal deliveries (after 10 h of labor) (n = 1) | •○○○ |
| Breslin et al., 2020 [21] USA   | n = 13 Mean maternal age 33.8 ± 5.2 | Case report  | Fever, subjective or measured (n = 12) | NR             | Third trimester (mean gestational age 33.3 ± 5.3) | Cesarean for acute respiratory decompensation (n = 5) | •○○○ |
| Breslin et al., 2020 [22] USA   | n = 43 Mean maternal age 29.7 ± 6.0 | Case series, retrospective | Symptomatic gestates (n = 29) | Worse fever or increased breathing work | Third trimester (≥37 weeks gestational age) | Cesarean delivery (n = 8) | ○○○ ○○ |
| Breslin et al., 2020 [23] USA   | n = 7 Age: 27 to 39 years | Case series  | Fever ≥37.0°C (100.0°F) (n = 2) | Severe hypertension | Third trimester (≥37 weeks gestational age) | Emergency cesarean section (n = 7) | •○○○ |
| Buonsenso et al., 2020 [24] Italy | n = 7 Age: 27 to 39 years | Observational study | NR | Low fever (37.5–38.5 °C) (n = 5) | Cesarean section (n = 2)—third trimester | Emergency cesarean section (n = 1) | •○○○ |
| Chen et al., 2020 [25] China    | n = 5 Age: 25 to 31 years | Descriptive study | Cough Sputum | Low fever (37.5–38.5 °C) (n = 5) | Third trimester (39–40 weeks) | Elective cesarean section (n = 1) (gestational diabetes) | •○○○ |
| Chen et al., 2020 [26] China    | n = 9 Age: 26 to 40 years | Descriptive, retrospective study | Low fever without chills (n = 7) | Fever (variation of 37.8–39.33 °C) (n = 6) | Third trimester (≥36 weeks gestational age) | Cesarean (n = 9) | •○○○ |
| First Author, Year, and Country | Study Size and Age | Study Design | Signs and Symptoms | Gestational Age | Type of Delivery and Maternal or Fetal Complications | GRADE * |
|---------------------------------|-------------------|-------------|--------------------|----------------|----------------------------------------------------------------|--------|
| Chen et al., 2020 [27] China   | n = 3 Age: 23 to 32 years | Descriptive, retrospective study | Fever and chest tightness (n = 1) Fever (n = 3) | Third trimester (≥35 weeks gestational age) | Emergency cesarean section (n = 3) | •○○○ |
| Chen et al., 2020 [26] China   | n = 17 Mean maternal age 29.7 years | Descriptive, retrospective study | Mild fever without chills (≤39 °C) (n = 4) Cough (n = 4) Fatigue (n = 1) Chest distress (n = 2) Diarrhea (n = 1) | NR | Third trimester (≥35 weeks gestational age) | Elective cesarean delivery (n = 14) Emergency cesarean delivery (n = 3) | •○○○ |
| Chen et al., 2020 [30] China   | n = 4 Age: 23 to 34 years | Case report | Fever (n = 3) Cough (n = 2) Fatigue (n = 2) Headache (n = 2) Dyspnea (n = 2) Anemia and dyspnea | Third trimester (≥33 weeks gestational age) | Cesarean section (n = 3) Vaginal delivery (n = 1) | •○○○ |
| Chen et al., 2020 [29] China   | n = 3 Age: 23 to 34 years | Case report | Cough (n = 3) Fever (n = 3) Fatigue (n = 3) Diarrhea, nausea, and vomiting | NR | First trimester (6 weeks) Second trimester (25 weeks) Third trimester (35 weeks) | Cesarean section delivery (n = 1) | •○○○ |
| Costa et al., 2020 [84] Italy  | n = 2 Age: 38 years and 42 years | Case report | Fever, shortness of breath, and diarrhea (n = 1) Cough (n = 1) | NR | Third trimester (n = 2) (≥34 weeks gestational age) | Caesarean section (n = 2) | •○○○ |
| Dong et al., 2020 [31] China   | n = 1 Age: 29 years | Case report | Fever, nasal congestion Liver injury | NR | Third trimester (34 weeks) | Cesarean section delivery (n = 1) | •○○○ |
| Elisegui et al., 2020 [72] Spain | n = 4 Age: 27 to 40 years | Case series | Mild clinical symptoms | NR | Second trimester | SARS-CoV-2 in vaginal discharge and amniotic fluid in Caucasian pregnant women affected by mild acute symptoms of COVID-19 | •○○○ |
| Facchetti et al., 2020 [83] Italy | n = 1 Age: 29 | Case report | Fever and idiopathic thrombocytopenia | NR | Third trimester (37 weeks gestational age) | Vaginal delivery was induced (n = 1) | •○○○ |
| Fan et al., 2020 [32] China    | n = 2 Age: 34 years and 29 years | Case report | Nasal congestion (n = 2) Fever (37.3–38.5 °C) (n = 2) Skin rash (n = 1) Chills (n = 1) Sore throat (n = 1) | NR | Third trimester (37 weeks gestational age) (36 weeks gestational age) | Cesarean section delivery (n = 2) | •○○○ |
| Ferrazzi et al., 2020 [33] Italy | n = 42 Mean maternal age 32.9 | Retrospective multicenter study | Fever (n = 20), cough (n = 7), myalgia/malaise (n = 7), dyspnea (n = 8) | NR | Third trimester (±30 weeks gestational age) | Elective cesarean (n = 18) Vaginal delivery (n = 24) | ⋄○○○ |
| Fenizia et al., 2020 [82] Italy | n = 31 Median age: 30 | Case report | Admission to ICU and invasive ventilation (n = 1) | NR | Third trimester (weeks median: 39) | Vaginal delivery (n = 25) Caesarean section (n = 6) | ⋄○○○ |
| Ferraiolo et al., 2020 [81] Italy | n = 1 Age: 30 | Case report | Asymptomatic | NR | Third trimester (38 weeks gestational age) | Urgent cesarean section | •○○○ |
### Table 1. Cont.

| First Author, Year, and Country | Study Size and Age | Study Design | Signs and Symptoms | Gestational Age | Type of Delivery and Maternal or Fetal Complications | GRADE * |
|---------------------------------|-------------------|--------------|-------------------|-----------------|------------------------------------------------------|--------|
| Fontanella et al., 2020 [34] the Netherlands and Ireland | n = 2 Age: 39 years and 29 years | Case report | Fever ≥37.3 °C (n = 2) (1) Cough and increasing dyspnea, thoracic pain with deep breathing (2) Productive cough, sore throat, and diarrhea | NR | Third trimester (31 weeks gestational age) (40 weeks gestational age) Cesarean (n = 2) | •••• |
| Gabriel et al., 2020 [80] Spain | n = 7 Median age: 33-43 | Observational prospective | Asymptomatic (n = 6) Fever, malaise, myalgia, headache (n = 1) | NR | Third trimester (≥38 weeks gestational age) Vaginal delivery (n = 6) Cesarean section (n = 1) | •••• |
| Gidlöff et al., 2020 [35] Sweden | n = 1 Age: 34 years | Case report | Hoarseness Increasing malaise Severe headache and photophobia Oxygen saturation dropped to 80% Pulmonary edema/embolism | NR | Third trimester (36 weeks gestational age) Emergency cesarean—dichorionic twin pregnancy (n = 2) | •••• |
| Hantoushzadeh et al., 2020 [36] Iran | n = 9 Age: 25 to 49 years | Case series | Fever (n = 9) Cough (n = 9) Dyspnea (n = 6) Myalgia (n = 4) | NR | Second trimester (n = 2) Third trimester (n = 7) Cesarean delivery (n = 6) Vaginal delivery (n = 1) | •••• |
| Hosier et al., 2020 [79] USA | n = 1 Age: 35 | Case report | Fever, malaise, nonproductive cough, diffuse myalgias, anorexia, nausea, and diarrhea | NR | Second trimester (22 weeks gestational age) Urgent cesarean section | •••• |
| Iqbal et al., 2020 [37] USA | n = 1 Age: 34 years | Case report | Fever, chills, dry cough, and myalgia Fever 38.5 °C | NR | Third trimester (39 weeks of gestation) Spontaneous vaginal delivery (n = 1) | •••• |
| Kalafat et al., 2020 [38] Turkey | n = 1 Age: 32 years | Case report | Nausea Dyspnea Swollen left leg | NR | Third trimester (35 weeks gestational age) Cesarean (n = 1) | •••• |
| Karami et al., 2020 [39] Iran | n = 1 Age: 27 years | Case report | Fever, cough, and myalgia for 3 days | NR | Third trimester (30 and 3/7 weeks gestation) Vaginal delivery (n = 1) | •••• |
| Khan et al., 2020 [5] China | n = 3 Age: 27 to 33 years | Case report | Cough (n = 3) Fever (≥37.3 °C) (n = 2) Chest tightness (n = 1) | NR | Third trimester (≥34 weeks of gestation) Vaginal delivery (n = 3) | •••• |
| Kirtsman et al., 2020 [40] Canada | n = 1 Age: 40 years | Case report | Cough Pyrexia Tachycardic (110-121 beats/min) Fever (39 °C) | NR | Third trimester (35 + 3 weeks gestation) Cesarean delivery (n = 1) | •••• |
| Knight et al., 2020 [41] UK | n = 427 Cohort study | | Fever (n = 280) Cough (n = 240) Breathlessness (n = 160) Tiredness or lethargy (n = 70) Headache (n = 60) | NR | Second trimester (≥26 weeks) (n = 4) Third trimester (>27 weeks) (n = 96) Cesarean, maternal indication due to SARS-CoV-2 (n = 42) Cesarean, other indication (n = 114) Operative vaginal (n = 28) Unassisted vaginal (n = 78) | ••••• |
| Lee et al., 2020 [7] Korea | n = 1 Age: 35 years | Case report | Fever (>38 °C), mild sore throat and cough | NR | Third trimester (37 weeks gestational age) Cesarean delivery (n = 1) | •••• |
| Li et al., 2020 [43] China | n = 16 Age: 26 to 37 years | Case-control study | Fever (n = 4) Cough (n = 4) | Fever (n = 8) | Third trimester (Mean weeks gestational age = 38 ± 0.2) Total: 17 babies Vaginal delivery (n = 2) Cesarean section (n = 14) Twin pregnancy | •••• |
| Li et al., 2020 [44] China | n = 1 Age: 30 years | Case report | Fever (37.2 °C), chills, or shortness of breath | NR | Third trimester (35 weeks gestational age) Emergency cesarean section (n = 1) | ••••• |
| First Author, Year, and Country | Study Size and Age | Study Design | Signs and Symptoms | Gestational Age | Type of Delivery and Maternal or Fetal Complications | GRADE * |
|--------------------------------|-------------------|-------------|-------------------|----------------|---------------------------------------------------|---------|
| Li et al., 2020 [42] China     | n = 1 Age: 31 years | Case report | Fever and dyspnea to acute respiratory distress syndrome and septic shock | NR | Third trimester (35 + 2 weeks gestational age) | Cesarean delivery (n = 1) | •○○○ |
| Liao et al., 2020 [46] China   | n = 15 Age: 23 to 40 years | Case report | Fever (n = 13) Cough (n = 9) Sore throat (n = 1) Dyspnea (n = 1) Myalgia (n = 3) Fatigue (n = 4) Diarrhea (n = 1) Asymptomatic (n = 2) | Fever (n = 1) | First and third trimesters (≥27 weeks gestational age) (12 to 38 weeks) | Cesarean section (n = 10) | •○○○ |
| Liu et al., 2020 [47] China    | n = 3 Age: 30 to 34 years | Case series study | Fever (37.8 °C) (n = 2) Cough (n = 2) | NR | Third trimester (>38 weeks gestational age) | Cesarean section (n = 2) | Natural childbirth (n = 1) | •○○○ |
| Lv et al., 2020 [78] China     | n = 1 Age: 28 | Case report | Fever and cough | NR | Third trimester (31 weeks gestational age) | Cesarean section |  |
| Lokken et al., 2020 [48] USA   | n = 46 Age: 26 to 34 years | Retrospective study | Symptomatic (n = 43) Cough (n = 30) Fever or chill (n = 22) Nasal congestion (n = 21) Shortness of breath/dyspnea (n = 19) (44.2%) Asymptomatic (n = 3) | NR | Second or third trimester | Vaginal (n = 5) Cesarean (n = 3) Preterm birth at 33 weeks (n = 1) | •○○○ |
| London et al., 2020 [49] USA   | n = 68 Age: ≥30 years | Retrospective cohort study | Fever (n = 46) Cough (n = 46) Shortness of breath (n = 46) Sore throat (n = 46) Nausea (n = 46) Vomiting (n = 46) Asymptomatic (n = 22) | NR | First trimester (17 weeks gestational age) (n = 1) Second trimester (25 and 26 weeks) (n = 2) Third trimester (n = 65) | Cesarean delivery (n = 22) | •○○○ |
| Lowe et al., 2020 [71] Australia | n = 1 Age: 31 years | Case report | Initially remained asymptomatic Fever | NR | Third trimester (40 weeks gestational age) | Vaginal delivery | •○○○ |
| Martinez-Perez et al., 2020 [50] Spain | n = 82 Age: 33 years | Cohort | Symptomatic gestates (n = 60) Asymptomatic pregnant women (n = 22) | NR | Third trimester (≥29 weeks gestational age) | Delivered vaginally (n = 49) Cesarean delivery (n = 33) | •○○○ |
| Patane et al., 2020 [51] Italy | n = 22 Age: 33 years | Retrospective cohort study | Fever 38 °C (n = 2) Dry cough (n = 2) | NR | Third trimester (≥37 weeks gestational age) | Vaginal delivery (n = 1) Cesarean delivery (n = 1) | •○○○ |
| Penfield et al., 2020 [52] USA | n = 32 Age: 22 to 40 years | Retrospective cohort study | NR | NR | Second and Third trimester (≥26 weeks) | Cesarean delivery (n = 4) Normal spontaneous vaginal delivery (n = 7) | •○○○ |
| First Author, Year, and Country | Study Size and Age | Study Design | Signs and Symptoms | Gestational Age | Type of Delivery and Maternal or Fetal Complications | GRADE * |
|--------------------------------|-------------------|-------------|-------------------|----------------|-------------------------------------------------|--------|
| Peng et al., 2020 [53] | n = 1 Age: 22 to 40 years | Case report | Fever, fatigue, shortness of breath | NR | Third trimester (35.2 weeks gestational age) | Cesarean (n = 1) | •••• |
| Pereira et al., 2020 [77] | n = 60 Median age: 34 years | Descriptive | Fever and cough | Admission to ICU (n = 1) (with HELLP syndrome) | Third trimester (median: 32 weeks) | During the study period, 23 women delivered: Cesarean section (n = 5) Vaginal (n = 18) | •••• |
| Qiancheng et al., 2020 [54] | n = 28 Mean maternal age 30.26.75–32 years | Single-center, retrospective study | Cough (n = 7) Fever (n = 5) Abdominal pain (n = 5) Dyspnea (n = 2) Malaise (n = 1) | NR | First trimester (n = 3) Second trimester (n = 1) Third trimester (n = 24) | Cesarean section (n = 17) Vaginal delivery (n = 5) | •••• |
| Siying et al., 2020 [57] | n = 38 Age: 15 to 48 years | Retrospective cohort study | Fever (n = 54) Cough (n = 62) Dyspnea (n = 27) | Symptomatic (n = 10) | First trimester (n = 4) Second trimester (n = 13) Third trimester (n = 50) | Cesarean (n = 31) Vaginal (n = 36) | •••• |
| Schwartz et al., 2020 [76] | n = 9 Age: 28 | Retrospective cohort study | NR | NR | Third trimester (>28 weeks gestational age) | Cesarean section (n = 8) Spontaneous vaginal delivery (n = 1) | •••• |
| Sentilhes et al., 2020 [56] | n = 38 Age: 19 to 42 years | Retrospective single-center study | Fatigue (n = 38) Cough (n = 25) Anosmia or ageusia (n = 18) Fever (n = 10) | NR | Third trimester (mean weeks gestational age 29.3 ± 8.5) | Cesarean (n = 6) Vaginal (n = 10) | •••• |
| Sisman et al., 2020 [75] | n = 1 Age: 37 | Case report | Fever | NR | Third trimester (34 weeks gestational age) | Vaginal delivery (n = 1) | •••• |
| Siying et al., 2020 [57] | n = 1 Age: 33 | Case report | Dry cough 1 day before admission, without sputum, sore throat, fatigue | Dry cough | Third trimester (37 weeks gestational age) | Emergency caesarean section (n = 1) | •••• |
| Vivanti et al., 2020 [74] | n = 1 Age: 23 | Case report | Fever (38.6 °C), severe cough, and abundant expectoration | NR | Third trimester (33 ± 2 weeks of gestation) | Cesarean delivery (n = 1) | •••• |
| Wang et al., 2020 [59] | n = 1 Age: 28 | Case report | Fever | NR | Third trimester (30 weeks pregnant) | Emergency cesarean (n = 1) | •••• |
| Xiong et al., 2020 [62] | n = 1 Age: 25 years | Case report | Fever (38 °C) Dry cough Shivering | NR | Third trimester (33 weeks gestational age) | Vaginal delivery six hours after (n = 1) | •••• |
Table 1. Cont.

| First Author, Year, and Country | Study Size and Age | Study Design | Signs and Symptoms | Gestational Age | Type of Delivery and Maternal or Fetal Complications | GRADE * |
|--------------------------------|------------------|-------------|-------------------|-----------------|-----------------------------------------------------|---------|
| Yan et al., 2020 [63] China   | 116 | Mean maternal age 30.8 ± 3.8 | Descriptive study, retrospective | Fever (n = 59) Cough (n = 33) Clinically asymptomatic (n = 27) | NR | Third trimester (≥38 weeks gestational age) Cesarean delivery (n = 85) Vaginal delivery (n = 14) | •••○ |
| Yang et al., 2020 [64] China  | 26 | Age: 21 to 40 years | Retrospective study | Fever (13 cases), cough (10 cases), vomiting (1 case) | NR | Third trimester (≥30 weeks gestational age) Cesarean section (n = 20); Vaginal (n = 6 cases) | •○○○ |
| Yang P et al., 2020 [65] China | 7 | Age: 21 to 40 years | Case report | Fever (n = 5) Cough (n = 1) Abdominal pain (n = 1) | Fever | Third trimester (≥36 weeks gestational age) Cesarean delivery (n = 7) | •○○○ |
| Yu et al., 2020 [66] China    | 7 | Age: 29 to 34 years | Descriptive study, retrospective | Fever (n = 6) Cough (n = 1) Shortness of breath (n = 1) Diarrhea (n = 1) | NR | Third trimester (≥37 weeks gestational age) Cesarean delivery (n = 7) | •○○○ |
| Yu et al., 2020 [67] China    | 1 | Age: 35 | Descriptive study, retrospective | Low fever and dry cough Dyspnea and cyanosis | NR | Third trimester (34 weeks gestational age) Vaginal delivery (n = 1) | •○○○ |
| Yue et al., 2020 [73] China   | 14 | Mean maternal age 30.1 ± 4.4 | Case series study | Fever (n = 4) | NR | Third trimester (mean weeks gestational age 38 ± 0.4) Emergency cesarean (n = 13) | •○○○ |
| Zeng et al., 2020 [68] China  | 33 | Age: 24 to 34 years | Case report | Cough (n = 10) Fever on admission (n = 8) | Fever (n = 5) | Third trimester (≥31 weeks gestational age) Cesarean delivery because of meconium-stained amniotic fluid Cesarean delivery (n = 26) Natural childbirth (n = 7) | •○○○ |
| Zhang et al., 2020 [69] China | 16 | Age: 24 to 34 years | Retrospective study | Cough (n = 3) Chest tightness (n = 3) Shortness of breath (n = 3) Diarrhea (n = 3) | NR | Third trimester (≥38 weeks gestational age) Cesarean section (n = 10) | •○○○ |
| Zhu et al., 2020 [70] China   | 9 | Mother of the twins (n = 1) Age: 25 to 34 years | Retrospective study | Fever (n = 7) Cough (n = 4) Diarrhea (n = 1) | NR | Third trimester (≥31 weeks gestational age) Cesarean section (n = 7) Vaginal delivery (n = 2) | •○○○ |

NR: Not reported; * Quality of evidence based on GRADE classification in four categories: Very low quality, low quality, moderate quality, or high quality.
The distribution of studies in terms of quality of evidence based on GRADE are as follows: High quality \( (n = 1) \) [41], moderate quality \( (n = 11) \) [9,21,22,33,48–50,52,55,63,68], low quality \( (n = 26) \) [5,9,23–26,28,29,36,40,43,46,47,51,54,56,60–62,64–67,69,70,73], and very low quality \( (n = 32) \) [7,18,20,27,30–32,34,35,37–39,42,44,45,53,57–59,66,71,72,74,75,77–81,83–85]. The studies that were classified as “low-quality” and “very low-quality” are case reports or small series of cases which also characterizes a high risk of bias.

3.2. Synthesis of Results

Of the 70 studies included, 34 were carried out in China [5,9,25–28,30–32,42–47,53,54,57–70,73,78], 10 in the United States [21–23,37,49,52,75,79,85], eight in Italy [24,33,51,55,81–84], three in Iran [36,39,76], one in Korea [7], one in Turkey [38], one in Peru [18], one in Switzerland [20], two in France [56,74], three in Spain [50,77,80], one in Australia [71], one in Spain [72], one in the Netherlands and Ireland [34], one in Canada [40], one in the United Kingdom [41], and one in Sweden [35].

A total of 1457 pregnant women diagnosed with COVID-19 and 1042 newborns from infected mothers were included. Maternal SARS-CoV-2 infection was diagnosed by reverse transcriptase–polymerase chain reaction (RT-PCR or PCR) of nasopharyngeal swabs and sputum samples [9].

3.3. Signs and Symptoms

Among infected pregnant women, 116 (7.9%) were asymptomatic at the beginning of medical care. Of the symptomatic pregnant women, the most frequent symptoms were fever (>37.3 °C) \( (n = 695, 47.7\%)\), cough \( (n = 647, 44.4\%)\), and nausea \( (n = 148, 10.2\%)\). Less common symptoms included dyspnea \( (n = 87, 6.5\%)\), fatigue \( (n = 58, 4.3\%)\), myalgia \( (n = 42, 2.9\%)\), and diarrhea \( (n = 14, 0.9\%)\). In the immediate postpartum period, the most frequent symptom was fever (37.8–39.33 °C).

3.4. Gestational Age

Twenty-one (1.4%) of the pregnant women were in the first trimester, 97 (6.6%) in the second trimester, and 1339 (91.9%) in the third trimester of pregnancy.

3.5. Type of Delivery

In terms of the type of delivery, 597 (57.3%) underwent elective cesarean section, 36 (3.4%) received emergency cesarean sections, and 364 (34.9%) went through spontaneous vaginal delivery.

3.6. Comorbidity and Pregnancy Complications

The most reported maternal comorbidities were obesity \( (n = 191, 13.1\%)\), hypertensive disorders \( (n = 117, 8.0\%)\), diabetes \( (n = 49, 3.3\%)\), asthma \( (n = 44, 3.0\%)\), and preeclampsia \( (n = 15, 1.0\%)\). Pregnancy complications included gestational diabetes \( (n = 91, 6.2\%)\) and gestational hypertension \( (n = 12, 0.8\%)\). Comorbidities and complications in pregnant women with COVID-19 are described in Table 2.

3.7. Maternal Outcomes

Among pregnant women diagnosed with COVID-19, 68 (4.6%) were admitted in intensive care units (ICU) [21–23,33,36,55,56,67,85]. There were 15 (1.0%) cases of maternal death [21,36,39,41], mostly from United Kingdom \( (n = 5) \) [41] and Iran \( (n = 7) \) [36]. Hantoushzadeh et al. [36] reported that pregnant women with SARS-CoV-2 infection in the second or third trimester of pregnancy can suffer cardiopulmonary complications and die.
Table 2. Comorbidities and complications in pregnant women diagnosed with COVID-19.

| Gestational Age | Comorbidity                                      | Complications                           |
|-----------------|-------------------------------------------------|-----------------------------------------|
| Second trimester| Psoriasis [79]                                   | Preeclampsia [79]                       |
|                 | Severe hypertension [79]                        |                                         |
|                 | Coagulopathy [79]                               |                                         |
| Third trimester | Asthma [21,23;50,56]                             | Abnormal placenta (placenta previa) [70]|
|                 | Chronic comorbidity [82]                        | Complete prior placenta [27]            |
|                 | Chronic hypertension [22;23]                     | Complications in pregnancy [73]         |
|                 | Type 2 diabetes mellitus [18;21–23;26;75]        | Gestational diabetes                    |
|                 | Dysfunction of blood coagulation [64]           |                                         |
|                 | Hepatitis B [9,43]                               | Gestational hypertension [9,21,25;36,64]|
|                 | History of frequent bacterial infections (sinusitis, skin infection, and bronchitis) during this pregnancy [40] | Pneumonia secondary to COVID-19 [85]    |
|                 | Asthma [21,23;35,41,43,63]                       | Sepsis [85]                             |
|                 | Hypertension [25,35,41,43,63]                    | Maternal COVID-19 pneumonia [68]        |
|                 | Hypothyroidism [59,64,66]                        | Intrauterine fetal distress [73]        |
|                 | Polycystic ovary syndrome [66]                   | Placental detachment [27]               |
|                 | Mild-intermittent asthma [22]                    | Preeclampsia [25,28,50,63,69]           |
|                 | Obesity [21,22,34,35,50,56,69,75]                | Previous placenta [30]                  |
|                 | Obstructive sleep apnea [21]                     | Severe preeclampsia [64]                |
|                 | Poly cystic ovarian syndrome [43]                |                                         |
| Second and third trimesters * | Asthma [41,46]                                        | Gestational diabetes [41,48]             |
|                 | Cardiac disease [41]                             | Gestational hypertension [48]           |
|                 | Diabetes [41]                                    |                                         |
|                 | Hypertension [41]                                |                                         |
|                 | Obese [41]                                       |                                         |
|                 | Overweight or obese [46]                         |                                         |
|                 | Type 2 diabetes [48]                             |                                         |
| First, second, and third trimesters * | Asthma [49]                                              | Gestational diabetes [49]              |
|                 | Autoimmune disease [55]                         | Preeclampsia [49]                       |
|                 | Chronic hepatitis B virus infection [54]         |                                         |
|                 | Chronic hypertension [49]                        |                                         |
|                 | Diabetes [49,54]                                 |                                         |
|                 | Endocrine disease [55]                           |                                         |
|                 | Hypertension [54]                                |                                         |
|                 | Hypothyroidism [54]                              |                                         |
|                 | Metabolic diseases [55]                          |                                         |
|                 | Obesity [55]                                     |                                         |

* There was no stratification of comorbidity and complications for the gestational semester.

3.8. Neonatal and Fetal Outcomes

Among neonates born to infected mothers, 187 (17.9%) required admission to neonatal ICUs [18,26,33,41,50,55,56,63,65,66,85]. There were 16 (1.5%) total cases of neonatal death and fetal intrauterine death [20,36,39,41,42,48,49,63,70]. Karami et al. reported a case of an infected pregnant woman who vaginally delivered a cyanotic fetus in the third trimester [39]. In the study by Zhu et al. [67], a newborn delivered at 34 + 5 weeks of gestation from a 30-year-old mother with COVID-19 experienced refractory shock, gastric bleeding, multiple organ failure, and disseminated intravascular coagulation. There were four total cases of fetal demise: One at 17 weeks [49] and three at the third trimester of pregnancy [42,48,63]. Lookken et al. [48] reported one case of stillbirth at 38.7 weeks in which the qualitative PCR tests of placental and fetal tissue were negative for SARS-CoV-2 and cytomegalovirus. However, the delay between fetal death and sample extraction for PCR analysis may have led to inaccurate results.

In the study by Li et al. [42], biochemical examination of umbilical cord blood at birth revealed a marked increase in myocardial enzymes, suggesting severe damage of the fetal myocardium. Considering severe hypoxia, the possibility of immunologic damage cannot be ruled out. This may have led to difficulties in resuscitation and eventually neonatal death. Maternal hypoxia and unstable circulation secondary to COVID-19 can endanger the fetus and cause intrauterine fetal death [42].
Among the seven total cases (0.7%) of miscarriage [20,24,41,56], the distribution by type are as follows: Spontaneous miscarriage (n = 1) [24], threatened miscarriage (n = 1) [29], medical miscarriage (n = 4) [54], and induced miscarriage (n = 1) [29].

Among various studies, there were 64 (6.1%) cases of premature birth [25,36,54,61,63,64,69,70,73,75–77,82,85], 10 (0.9%) patients with complications in pregnancy [73], and 28 (2.7%) cases of intrauterine fetal distress [25,47,48,53,60,63–70,73,84].

Decreased fetal movements were reported for 19 (1.8%) fetuses [21,30,36–38,49,57,58,68,69]. There were five (0.5%) cases of severe neonatal asphyxia [63,64,69] and four (0.3%) cases of low birth weight (<2500 g) in the third pregnancy trimester [25,63]. Abnormal fetal heart monitoring [29], fetal tachycardia [28,34], and placental detachment [48] were also reported. Other outcomes include premature rupture of membranes (n = 26, 2.5%) [36,50,62,69,86], abnormal amniotic fluid (n = 3, 0.3%) [69,70], and abnormal umbilical cord in the third pregnancy trimester (n = 6, 0.6%) [64,70].

3.9. Newborns and Placental and Breast Milk Samples Tested Positive for SARS-COV-2

Of the 70 studies analyzed, 21 studies included a total of 39 (3.7%) newborns who tested positive for SARS-CoV-2 [18,24,33,36,40,41,50,51,55,58,66,68,74–76,82,83]. In only five studies (23.8%), newborns were tested within the first 12 h of birth [33,41,50,74,76]. Two studies have presented neonates with symptoms; however, tests for SARS-CoV-2 were negative [32,35]. SARS-CoV-2 RNA was detected in 13 placenta samples [20,51,52,74,79,81–83,85] and six breast milk samples of infected pregnant women [61,82,84]. There was also a positive test for SARS-CoV-2 RT-PCR in umbilical cord and vagina samples [82] (Table 3). In addition, one newborn received an inconclusive result but was otherwise asymptomatic [22]. Twelve newborns presented IgG positive in umbilical cord plasma [82] and two neonates born to a mother with COVID-19 had elevated antibody levels (IgM) 2 h after birth [31,82].

3.10. Newborns Tested Negative for SARS-COV-2 and Vertical Transmission

A total of 959 newborns were asymptomatic at birth and had negative results for SARS-CoV-2. The distribution of oropharyngeal swab collection time for RT-PCR among studies in which newborns were negative are as follows: At birth (n = 51) [21,24,31–36,38,44,47–49,51,54,56,58,61,70,71,73,77,78,80], 72 h after birth (n = 1) [70], fifth day (n = 1) [69], seventh and ninth days (n = 1) [70], and fourth to fourteenth days (n = 1) [46].

In addition to oropharyngeal swabs, other samples for testing included placental tissue [7,26,27,29,30,32,38,44,47,53,58,59,62,78], fetal membrane [27], umbilical cord blood [5,7,20,29,32,38,44,45,53,58,59,65,78], breast milk [25,29,31,32,35,38,44,45,47,53,57,58,80], amniotic fluid [7,20,25,29,44,45,53,59,62,65,78], serum [32,53], bronchoalveolar lavage fluid [53], vaginal secretions [20,31,32,53], axillary swab [20], mouth swab [20], neonatal gastric fluid [78], meconium [20], urine [44,45,53], rectal swab samples [24,56], feces [44,45,57], and anal swab [53,61,78]. In addition to RT-PCR, other tests such as IgM and IgG antibody [31,64], cytokine [31], and blood biochemistry tests [31] were also used. The results of all the various tests using a myriad of samples were negative.

In one study, the presence of SARS-CoV-2 was investigated in vaginal discharge and amniotic fluid in four pregnant women with mild acute symptoms of COVID-19 who underwent amniocentesis during the second trimester of pregnancy [72]. In addition, in another study, a case of vaginal delivery without complications was described in a mother with COVID-19 [47]. The test for neonatal COVID-19 24 h after delivery was still negative despite the fact that the infant was breastfed and not separated from the mother [71].
### Table 3. Results for newborn placentas and breast milk that tested positive for SARS-CoV-2 after birth.

| First Author and Year | Diagnosis Test | Type of Delivery | Positive COVID-19 Test Results |
|-----------------------|----------------|------------------|--------------------------------|
| **NEWBORNS**          |                |                  |                                |
| Alzamora et al., 2020 [18] | Nasopharyngeal swab was obtained for SARS-CoV-2 RT-PCR | Emergency cesarean section (n = 1) | Nasopharyngeal swab, 16 h after delivery, was positive for SARS-CoV-2 RT-PCR, and immunoglobulin (Ig)-M and IgG for SARS-CoV-2: Negative |
| Buonsenso et al., 2020 [24] | RT-PCR | Cesarean section (n = 1) | SARS-CoV-2 positive at 15 days of life, although asymptomatic |
| Facchetti et al., 2020 [83] | SARS-CoV-2 RNA on nasopharyngeal swab | Vaginal delivery was induced (n = 1) | Resulted inconclusive (amplification of less than three genes), while it was positive 36 and 72 h after birth and at the age of 17 days |
| Fenizia et al., 2020 [82] | Nasopharyngeal newborn swab was obtained for SARS-CoV-2 RT-PCR after the baby was cleaned | Vaginal delivery (n = 25) Cesarean section (n = 6) | Viral RNA positive in newborns (n = 2) |
| Ferrazzi et al., 2020 [33] | RT-PCR | (1) Elective cesarean section (n = 2) (2) Vaginal delivery (n = 1) | (1) Newborns had a positive test for COVID-19 infection at days one and three, respectively (2) The first test for SARS-CoV-2 was equivocal a few hours after delivery, but positive three days later |
| Hantoushzadeh et al., 2020 [36] | SARS-CoV-2 NAT | Cesarean section (n = 1) | Negative on day 1 of life but converted to positive on day 7 of life with an accompanying lymphopenia (nadir white blood cell 8.9, with 26% lymphocytes) The neonate was intubated for prematurity, developed pneumonia at day of life 2 There was maternal death |
| Knight et al., 2020 [41] | Detection of viral RNA on polymerase chain reaction testing of blood or a nasopharyngeal swab or aspirate | Cesarean section (n = 4) Vaginal birth (n = 2) | Positive test <12 h of age (n = 6) Positive test ≥12 h of age 6 (n = 6) |
| Kirtsman et al., 2020 [40] | RT-PCR Placental swabs (both maternal and fetal sides) were obtained Placental tissue was sent for PCR and histopathologic examination Nasopharyngeal swabs were obtained from the neonate on the day of birth, day 2, and day 7, after thorough cleansing of the baby and before contact with the mother | Cesarean section (n = 1) | All 3 of the neonate’s nasopharyngeal swabs were positive for SARS-CoV-2 gene targets via RT-PCR testing; neonatal plasma tested positive on day 4, and stool was positive on day 7 |
| First Author and Year | Diagnosis Test | Type of Delivery | Positive COVID-19 Test Results |
|-----------------------|----------------|-----------------|--------------------------------|
| Martinez-Perez et al., 2020 [50] | SARS-CoV-2 RNA RT-PCR | Vaginal delivery $(n = 2)$ Cesarean section $(n = 1)$ | Three newborns tested within 6 h after birth had a positive SARS-CoV-2 RT-PCR result. Repeat testing at 48 h was negative. None developed COVID-19 symptoms within 10 days. |
| Patanè et al., 2020 [51] | SARS-CoV-2 RNA RT-PCR | Vaginal delivery $(n = 1)$ Cesarean section $(n = 1)$ | (1) The newborn had positive NP swabs immediately at birth, after 24 h, and after 7 days; he remained asymptomatic. (2) Neonatal NP swab was 60 positive at birth and turned positive on day 7, with no contact between mother and neonate during that period. |
| Savasi et al., 2020 [55] | Pharyngeal swab sampled for SARS-CoV-2 | Vaginal delivery $(n = 3)$ Cesarean section $(n = 1)$ | Positive on the seventh day $(n = 1)$. |
| Schwartz et al., 2020 [76] | Infant RT-PCR testing | Cesarean section $(n = 8)$ Spontaneous vaginal delivery $(n = 1)$ | Positive by RT-PCR for SARS-CoV-2 $(n = 9)$: 1 h after delivery $(n = 1)$ 2 h after delivery $(n = 1)$ DOL 2 $(n = 1)$ DOL 3 $(n = 1)$ DOL 4 $(n = 2)$ DOL 6 $(n = 1)$ DOL 7 $(n = 1)$ DOL 24 $(n = 1)$ |
| Sisman et al., 2020 [75] | Nasopharyngeal swab by RT-PCR for SARS-CoV-2 at 24 and 48 h of life | Vaginal delivery $(n = 1)$ | Positive by nasopharyngeal swab. |
| Vivanti et al., 2020 [74] | Nasopharyngeal and rectal swabs were first collected after having cleaned the baby at 1 h of life, and they were tested with RT-PCR Blood and nonbronchoscopic bronchoalveolar lavage fluid were collected for RT-PCR | Cesarean delivery $(n = 1)$ | Nasopharyngeal and rectal Blood and nonbronchoscopic bronchoalveolar lavage fluid Clear amniotic fluid was collected prior to rupture of membranes during cesarean section and tested positive for both the E and S genes of SARS-CoV-2. |
| Zeng et al., 2020 [68] | SARS-CoV-2 real-time reverse transcriptase–polymerase | Cesarean section $(n = 3)$ | (1) Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life. (2) Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life and negative on day 6. (3) Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life and negative on day 7. |
| Wang et al., 2020 [65] | SARS-CoV-2 RNA RT-PCR Pharyngeal swab | Emergency cesarean section $(n = 1)$ | The result of pharyngeal swab for SARS-CoV-2 was positive at 36 h after birth. |
| First Author and Year | Diagnosis Test                                                                 | Type of Delivery          | Positive COVID-19 Test Results                                                                                                                                                                                                 |
|----------------------|--------------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Yu et al., 2020 [67] | RT-PCR for SARS-CoV-2                                                           | Cesarean section (n = 1) | Nucleic acid test for the throat swab of one neonate (child of patient 1) was positive at 36 h after birth                                                                                                                |
| Fenizia et al., 2020 [82] | Umbilical cord plasma: SARS-CoV-2 RT-PCR and SARS-CoV-2 IgG and IgM chemiluminescence immunoassay | Vaginal delivery (n = 25) | Viral RNA positive + IgG positive in umbilical cord plasma (n = 1)                                                                                                                                   |
| Fenizia et al., 2020 [82] | Vaginal swab: SARS-CoV-2 RT-PCR                                                | Vaginal delivery (n = 25) | Elevated IgM level of SARS-CoV-2 2 h after her birth Testing on her nasopharyngeal swab was negative (tested twice)                                                                                     |
| Yang et al., 2020 [64]  | RT-PCR for SARS-CoV-2 SARS-CoV-2 IgM/IgG antibodies rapid test kit              | Cesarean section (n = 1) | Symptoms, suspected case: Two babies showed symptoms but failed to detect SARS-CoV-2 in any of the samples, including the newborn’s nasopharyngeal swab, maternal serum, placental tissues, umbilical cord blood, amniotic fluid, vaginal swabs, and breast milk |
| Fan et al., 2020 [32]   | RT-PCR nasopharyngeal swab, maternal serum, placental tissues, umbilical cord blood, amniotic fluid, vaginal swabs, and breast milk | Cesarean section (n = 2) | Twins symptoms, suspected cases: At 22 min after delivery developed breathing problems On the second day, she had a cyanotic attack while feeding Both twins had negative nasophopharyngeal COVID-19 tests taken at 34 h and 4.5 days of age COVID-19 tests performed on breast milk and maternal vaginal secretion on the fifth day were also negative |
| First Author and Year | Diagnosis Test | Type of Delivery | Positive COVID-19 Test Results |
|-----------------------|----------------|-----------------|--------------------------------|
| **Table 3. Cont.**    |                |                 |                                |
| **Placenta**          |                |                 |                                |
| Algarroba et al., 2020| Electron microscopy | Cesarean delivery | A single virion was visible invading a syncytiotrophoblast A single virion was also visualized in a microvillus |
| Baud et al., 2020 [20]| Maternal—RT-PCR  | Deep nasopharyngeal control | Placental submembrane—positive sterile Placental cotyledon—positive |
|                       | Vagina          | Deep nasopharyngeal control |                                      |
|                       | Blood           | Fetus—RT-PCR        |                                      |
|                       | Umbilical cord blood | Amniotic fluid negative sterile |                                      |
|                       | Placental submembrane | Fetal armpit |                                      |
|                       | Placental cotyledon | Fetal anus |                                      |
|                       | Fetal artery    | Fetal liver |                                      |
|                       | Fetal thymus    | Fetal thymus |                                      |
|                       | Fetal lung      | Fetal lung |                                      |
| Baud et al., 2020 [20]| Vaginal delivery (n = 1) |                                      |                                |
| Facchetti et al., 2020[83]| Histological, immunohistochemical, in situ | Vaginal delivery was induced (n = 1)—third trimester | Placenta: Tested positive for SARS-CoV-2, after detecting the presence of S-protein-specific transcripts by RNA-in situ hybridization; immunostains for SARS-CoV-2 proteins showed positivity in the cytoplasm of the syncytiotrophoblast for both S-protein and n-protein |
| Fenizia et al., 2020  [82]| SARS-CoV-2 RTPCR | Vaginal delivery (n = 25) Caesarean section (n = 6) | Viral RNA positive in placenta (n = 2) |
| Ferraiolo et al., 2020| SARS-CoV-2 RTPCR | Urgent cesarean section (n = 1)—third trimester | The definitive histological analysis of the placenta did not describe substantial macroscopic alterations, except for mild subchorionic deposition of fibrin and for the presence of a single ischemic area in the thickness of the chorionic disc |
| Hosier et al., 2020   | SARS-CoV-2 RTPCR | Urgent cesarean section (n = 1)—second trimester | Placenta and umbilical cord were positive for SARS On histological examination, SARS-CoV-2 localized predominantly to the syncytiotrophoblast cells of the placenta Analysis of the placental region adjacent to the umbilical cord identified virus particles within the cytosol of placental cells consistent with the size and appearance of SARS-CoV-2 |
Table 3. Cont.

| First Author and Year   | Diagnosis Test                                | Type of Delivery | Positive COVID-19 Test Results |
|-------------------------|-----------------------------------------------|------------------|--------------------------------|
| Penfield et al., 2020 [52] | SARS-CoV-2 RNA RT-PCR                         | Cesarean section (n = 3) | Infected placentas (n = 1) or membrane swabs (n = 2) |
| Patanè et al., 2020 [51] | SARS-CoV-2 RNA RT-PCR                         | Vaginal delivery (n = 1) Cesarean section (n = 1) | SARS-CoV-2 RNA in the placentas |
| Vivanti et al., 2020 [74] | SARS-CoV-2 RNA RT-PCR                         | Cesarean delivery (n = 1) Third trimester | Placental infection as positive for SARS-CoV-2 RNA |
|                          |                                               |                  |                                |
|                          |                                               |                  |                                |
| Breast Milk             |                                               |                  |                                |
| Costa et al., 2020 [84]  | SARS-CoV-2 RT-PCR in six breast milk samples | Cesarean delivery (n = 2)—third trimester | Three of six breast milk samples (50%) had a cycle threshold value <40 (the value interpreted as positive for SARS-CoV-2 RNA), indicating that patient 1 excreted virus in her breast milk, albeit intermittently (n = 1) |
| Fenizia et al., 2020 [82]| SARS-CoV-2 RNA RT-PCR and SARS-CoV-2 IgG and IgM chemiluminescence immunoassay | Vaginal delivery (n = 25) Caesarean section (n = 6) Third trimester | Viral RNA positive and IgM positive in breast milk (n = 1) |
| Wu et al., 2020 [61]    | SARS-CoV-2 RNA RT-PCR—1st day after delivery Breast milk samples from three women were collected on the 1st, 6th, and 27th days after delivery Vaginal swabs Neonatal throat and anal swabs were collected on the 1st and 3rd days after birth | Caesarean section (n = 4) Natural delivery (n = 1) | Detection of SARS-CoV-2 in breast milk |

RT-PCR: Reverse transcriptase—polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; DOL: Days of life.
4. Discussion

This systematic review gathered evidence available on pregnancy and SARS-CoV-2 infection from the international literature to investigate signs and symptoms, type of delivery, comorbidities, clinical outcomes (maternal and neonatal), and vertical transmission risk of COVID-19. This study included a significant number of newborns and pregnant women diagnosed with COVID-19 in the first, second, and third trimesters of pregnancy. Although most studies which were included were case reports or case series that have low levels of evidence quality, these are still important in the current context due to the need for information to support public health policies.

In terms of signs and symptoms of COVID-19, fever above 37.0 °C was the most frequent symptom reported by pregnant women, followed by cough and nausea in the prenatal period. In the postpartum period, subjects were reported to experience fever (37.8–39.33 °C) and a general worsening of the condition, especially in those who were initially asymptomatic. Among symptomatic pregnant women, 4.99% were admitted in the ICU. The results in our study are consistent with those of studies in the general population, where fever and coughing were the most reported symptoms [87].

Obesity and hypertensive disorders were the most reported comorbidities in pregnant women with COVID-19. It is noted that the majority of the pregnant women did not have serious complications, with a low occurrence of maternal death (1.0%) and premature rupture of the membrane (2.5%). However, pregnancy complications, including gestational diabetes and gestational hypertension, were reported. Many pregnant women presented with worsening of the general condition that required an induced delivery or emergency cesarean section. However, we found that the maternal risk in pregnant women diagnosed with COVID-19 was relatively low.

In contrast, 17.9% of newborns were admitted in the neonatal ICU. Fetal and neonatal complications including premature delivery (6.1%), fetal distress (2.7%), decreased fetal movements (1.8%), and fetal and neonatal death (1.5%) were identified. There were also cases of miscarriage and severe neonatal asphyxia. Therefore, we hypothesize that there is a greater risk of fetal and neonatal complications in the first and second trimesters of pregnancy.

This systematic review included cases where SARS-CoV-2 RNA was detected in the placenta (n = 13), breast milk (n = 6), and neonates (n = 39). It is important to note that only five studies confirmed a diagnosis within the first 12 h of birth. In other studies, SARS-CoV-2 was detected 12 h after birth, hinting at the possibility of late-onset neonatal infection. Nevertheless, we highlight that 92% of newborns from mothers infected with COVID-19 did not acquire the infection during birth.

Although there is a theoretical risk of vertical transmission, it seems to be low and, so far, remains poorly understood. It has been reported that the placental barrier does not allow for the passage of SARS-CoV-2 [88]. However, there is evidence of histopathologic placental changes in women infected with COVID-19, showing poor maternal vascular perfusion and inflammation [89]. It is not clear whether this can disrupt the maternal–placental interface to allow the transplacental transmission of SARS-CoV-2 [89]. Furthermore, its role in the occurrence of premature births and other fetal complications remains unknown. Thus, more robust studies, preferably longitudinal studies, involving a large sample size with long-term follow-up are crucial to establish the full implications of COVID-19 on pregnancy and early development. It is unclear whether maternal and newborn COVID-19 infection will cause any sequelae in childhood. Nevertheless, it is essential to formulate guidelines for the management of pregnant women infected with SARS-CoV-2 as a way to minimize viral exposure and transmission [7]. These protocols also play important roles in protecting the medical team and providing a suitable hospital environment (e.g., respiratory precautions, use of personal protective equipment, and negative pressure rooms) [90].

The Lancet Infectious Diseases has published guidelines on the management of pregnant women exposed to COVID-19. For asymptomatic cases, home isolation for 14 days is recommended. In symptomatic cases, key recommendations include prioritization of vaginal delivery when possible, late fixation of the umbilical cord, without early cleaning of the newborn, and isolated neonatal surveillance. In both cases, mother–child separation and breastfeeding are discussed individually by an
interdisciplinary team [19]. In addition, a recent guideline published in June recommends that for cases where separation is not applicable, other measures to reduce risk of infection (e.g., physical barriers and face mask) must be adopted. For those who choose to breastfeed, mothers must wear face masks and practice good hygiene (hand and breast) before each feeding. Newborns from mothers with confirmed or suspected COVID-19 at the time of the delivery should be tested 24 h after birth. If negative, another test at approximately 48 h must be done if testing capacity is available [91].

4.1. Strengths and Limitations

This review was completed after an extensive bibliographic search using two databases, reference lists, and Google Scholar. We included a large number of pregnant women diagnosed with COVID-19 from 16 countries and data on the first, second, and third trimesters of pregnancy. However, our study has some limitations: First, our findings are mostly limited to case reports and retrospective studies with a small number of cases analyzed. Second, there was a lack of methodological criteria in the conduction of many included studies, which can contribute to erroneous results. However, it is important to highlight that we have gathered all the evidence available in the literature to date and that this information is important to guide health and management policies for pregnant women affected by COVID-19 in the first, second, and third trimesters of pregnancy. In addition, the justification for conducting our study is the need to quickly assess and discuss the evidence that has been generated. Finally, some relevant publications may have been released during the submission or publication process of this paper.

4.2. Future Recommendations

With the worsening of the COVID-19 global situation, new well-designed research is needed to clarify the risk of vertical transmission (via placenta or hematogenous routes, birth canal, and lactation) of SARS-CoV-2. In addition, further studies are necessary to investigate potential therapeutic interventions that prevent maternal and neonatal morbidity and possible sequelae resulting from COVID-19 infection. In addition, it is important that future studies assess complications arising from COVID-19 in pregnant women in the first and second trimester. These studies are important to improve clinical and preventive strategies for managing COVID-19 in pregnant women and their newborns.

5. Conclusions

This review revealed that pregnant women with COVID-19 usually present with fever, cough, and nausea. Among various comorbidities, obesity and hypertensive disorders are the most common. It is important to highlight the prevalence of premature birth, maternal death, premature rupture of the membrane, intrauterine fetal death, neonatal death, miscarriage, decreased fetal movements, and severe neonatal asphyxia among cases of infected mothers. Although we found only 27 cases of newborns infected with COVID-19, viral exposure of SARS-CoV-2 during pregnancy and intrapartum period cannot be ruled out and should be further investigated in future studies. Thus, it is important to follow-up all newborns from mothers diagnosed with COVID-19.

Author Contributions: Conceptualization, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; methodology, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; formal analysis, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; resources, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; data curation, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; writing—original draft preparation, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; writing—review and editing, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; visualization, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; supervision, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; funding acquisition, W.N.d.A. and M.N. All authors have read and agreed to the published version of the manuscript.

Funding: This work was carried out with its own financing.

Acknowledgments: Instituto Federal Goiano and Universidade Federal de Goiás for partial supporting.

Conflicts of Interest: The authors declare no conflict of interest.
22. Breslin, N.; Baptiste, C.; Gyamfi-Bannerman, C.; Miller, R.; Martinez, R.; Bernstein, K.; Ring, L.; Landau, R.; Purisich, S.; Friedman, A.M.; et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am. J. Obstet Gynecol MFM* 2020, 2, 100111. [CrossRef] [PubMed]

23. Breslin, N.; Baptiste, C.; Miller, R.; Fuchs, K.; Goffman, D.; Gyamfi-Bannerman, C.; D’Alton, M. COVID-19 in pregnancy: Early lessons. *Am. J. Obstet Gynecol. MFM* 2020, 2, 100111. [CrossRef] [PubMed]

24. Buonsenso, D.; Costa, S.; Sanguinetti, M.; Cattani, P.; Posteraro, B.; Marchetti, S.; Carducci, B.; Lanzone, A.; Tamburrini, E.; Vento, G. Neonatal late onset infection with severe acute respiratory syndrome Coronavirus 2. *J. Perinatol.* 2020, 37, 869–872.

25. Chen, H.; Guo, J.; Wang, C.; Luo, F.; Yu, X.; Zhang, W.; Li, J.; Zhao, D.; Xu, D.; Gong, Q.; et al. Clinical characteristics and intratracheal vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. *Lancet* 2020, 395, 809–815. [CrossRef]

26. Chen, R.; Zhang, Y.; Huang, L.; Cheng, B.H.; Xia, Z.Y.; Meng, Q.T. Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: A case series of 17 patients. *Can. J. Anaesth.* 2020, 67, 655–663. [CrossRef]

27. Chen, S.; Huang, B.; Luo, D.J.; Li, X.; Yang, F.; Zhao, Y.; Nie, X.; Huang, B.X. Pregnant women with new coronavirus infection: A clinical characteristics and placental pathological analysis of three cases. *Zhonghua Bing Li Xue Za Zhi Chin.* J. Pathol. 2020, 49, E005.

28. Chen, S.; Liao, E.; Cao, D.; Gao, Y.; Sun, G.; Shao, Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. *J. Med. Virol.* 2020, 92, 1556–1561. [CrossRef]

29. Chen, X.; Li, Y.; Wang, J.; Cai, H.; Cao, H.; Sheng, J. Pregnant women complicated with COVID-19: A clinical analysis of 3 cases. *Zhejiang Da Xue Xue Bao. Yi Xue Ban J. of Zhejiang Univ. Med. Sci.* 2020, 49, 240–244.

30. Chen, Y.; Peng, H.; Wang, L.; Zhao, Y.; Zeng, L.; Gao, H.; Liu, Y. Infants Born to Mothers with a New Coronavirus (COVID-19). *Front. Pediatr.* 2020, 8, 104. [CrossRef]

31. Dong, L.; Tian, J.; He, S.; Zhu, C.; Wang, J.; Liu, C.; Yang, J. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *JAMA* 2020, 323, 1846–1848. [CrossRef] [PubMed]

32. Fan, C.; Lei, D.; Fang, C.; Li, C.; Wang, M.; Liu, Y.; Bao, Y.; Sun, Y.; Huang, J.; Guo, Y.; et al. Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry? *Clin. Infect. Dis* 2020. [CrossRef] [PubMed]

33. Ferrazzi, E.; Frigerio, L.; Savasi, V.; Vergani, P.; Prefumo, F; Barresi, S.; Bianchi, S.; Ciriello, E.; Facchinetti, F.; Gervasi, M.T.; et al. Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: A retrospective analysis. *BJOG* 2020, 127, 1116–1121. [CrossRef] [PubMed]

34. Fontanella, F.; Hannes, S.; Keating, N.; Martyn, F.; Browne, I.; Briet, J.; McAuliffe, F.M.; Baalman, J.H. COVID-19 infection during the third trimester of pregnancy: Current clinical dilemmas. *Eur J. Obstet. Gynecol Reprod. Biol.* 2020, 251, 268–271. [CrossRef] [PubMed]

35. Gadiöf, S.; Savchenko, J.; Brune, T.; Josefsson, H. COVID-19 in pregnancy with comorbidities: More liberal testing strategy is needed. *Acta Obstet. Et Gynecol. Scand.* 2020, 99, 948–949. [CrossRef] [PubMed]

36. Hantoushzadeh, S.; Shamshirsaz, A.A.; Aleyasin, A.; Seferovic, M.D.; Aski, S.K.; Arian, S.E.; Pooransari, P.; Ghobizadeh, F.; Aalipour, S.; Soleimani, Z.; et al. Maternal death due to COVID-19. *Am. J. Obstet Gynecol MFM* 2020, 223, 109.e1–109.e16. [CrossRef]

37. Iqbal, S.N.; Overcash, R.; Mokhtari, N.; Saeed, H.; Gold, S.; Auguste, T.; Mirza, M.U.; Ruiz, M.E.; Chahine, J.J.; Waga, M.; et al. An Uncomplicated Delivery in a Patient with Covid-19 in the United States. *N. Engl. J. Med.* 2020, 382, e34. [CrossRef]

38. Kalafat, E.; yapark, E.; Cinar, G.; Varli, B.; Ozisik, S.; Uzun, C.; Azap, A.; Koc, A. Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. *Ultrasound Obstet. Gynecol.* 2020, 55, 835–837. [CrossRef]

39. Karami, P.; Naghavi, M.; Feyzi, A.; Aghamohammadi, M.; Novin, M.S.; Mobaien, A.; QorbaniSani, M.; Karami, A.; NooroZnezhad, A.H. WITHDRAWN: Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings. *Travel Med. Infect. Dis.* 2020, 101665. [CrossRef]

40. Kirtsman, M.; Diambomba, Y.; Poutanen, S.M.; Malinowski, A.K.; Vlahodimitropoulou, E.; Parks, W.T.; Erdman, L.; Morris, S.K.; Shah, P.S. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. *Can. Med. Assoc. J.* 2020, 192, E647–E650. [CrossRef]
41. Knight, M.; Bunch, K.; Vousden, N.; Morris, E.; Simpson, N.; Gale, C.; O’Brien, P.; Quigley, M.; Brocklehurst, P.; Kurinczuk, J.J. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: National population-based cohort study. *BMJ (Clin. Res. Ed.)* 2020, 369, m2107. [CrossRef] [PubMed]

42. Li, J.; Wang, Y.; Zeng, Y.; Song, T.; Pan, X.; Jia, M.; He, F.; Hou, L.; Li, B.; He, S.; et al. Critically ill pregnant patient with COVID-19 and neonatal death within two hours of birth. *Int. J. Gynecol. Obstet.* 2020, 150, 126–128. [CrossRef] [PubMed]

43. Li, N.; Han, L.; Peng, M.; Lv, Y.; Ouyang, Y.; Liu, K.; Yue, L.; Li, Q.; Sun, G.; Chen, L.; et al. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: A case-control study. *Clin. Infect. Dis.* 2020. [CrossRef]

44. Li, Y.; Zhao, R.; Zheng, S.; Chen, X.; Wang, J.; Sheng, X.; Zhou, J.; Cai, H.; Fang, Q.; Yu, F.; et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. *Emerg. Infect. Dis.* 2020. [CrossRef]

45. Liao, X.; Yang, H.; Kong, J.; Yang, H. Chest CT Findings in a Pregnant Patient with 2019 Novel Coronavirus Disease. *Balk. Med. J.* 2020. [CrossRef]

46. Liu, D.; Li, L.; Wu, X.; Zheng, D.; Wang, J.; Yang, L.; Zheng, C. Pregnancy and Perinatal Outcomes of Women with Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. *AJR Am. J. Roentgenol.* 2020, 215, 127–132. [CrossRef] [PubMed]

47. Liu, W.; Wang, Q.; Zhang, Q.; Chen, L.; Chen, J.; Zhang, B.; Lu, Y.; Wang, S.; Xia, L.; Huang, L. Coronavirus disease 2019 (COVID-19) during pregnancy: A case series. Available online: https://www.preprints.org/manuscript/202002.0373/v1. (accessed on 18 November 2020).

48. Lokken, E.M.; Walker, C.L.; Delaney, S.; Kachikis, A.; Kretzer, N.M.; Erickson, A.; Resnick, R.; Vanderhoeven, J.; Wang, J.K.; Barnhart, N.; et al. Clinical Characteristics of 46 Pregnant Women with a SARS-CoV-2 Infection in Washington State. *Am. J. Obstet. Gynecol. MFM* 2020. [CrossRef]

49. London, V.; McLaren, R., Jr.; Atallah, F.; Cepeda, C.; McCalla, S.; Fisher, N.; Stein, J.L.; Haberman, S.; Minkoff, H. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. *Am. J. Perinatol.* 2020, 37, 991–994. [CrossRef]

50. Martínez-Perez, O.; Vouga, M.; Cruz Melguizo, S.; Forcen Acebal, L.; Panchaud, A.; Muñoz-Chápuli, M.; Baud, D. Association Between Mode of Delivery Among Pregnant Women With COVID-19 and Maternal and Neonatal Outcomes in Spain. *JAMA* 2020, 324, 296. [CrossRef]

51. Patanè, L.; Morotti, D.; Giunta, M.R.; Sigismondi, C.; Piccoli, M.G.; Frigerio, L.; Mangili, G.; Arosio, M.; Cornolli, G. Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth. *Am. J. Obstet. Gynecol. MFM* 2020, 2, 100145. [CrossRef]

52. Penfield, C.A.; Brubaker, S.G.; Limaye, M.A.; Lighter, J.; Ratner, A.J.; Thomas, K.M.; Meyer, J.; Roman, A.S. Detection of SARS-COV-2 in Placental and Fetal Membrane Samples. *Am. J. Obstet. Gynecol. MFM* 2020, 2, 100133. [CrossRef] [PubMed]

53. Peng, Z.; Wang, J.; Mo, Y.; Duan, W.; Xiang, G.; Yi, M.; Bao, L.; Shi, Y. Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report. *J. Infect. Public Health* 2020, 13, 818–820. [CrossRef]

54. Qiancheng, X.; Jian, S.; Lingling, P.; Lei, H.; Xiaogan, J.; Weihua, L.; Gang, Y.; Shirong, L.; Zhen, W.; Guoping, X.; et al. Coronavirus disease 2019 in pregnancy. *Int. J. Infect. Dis.* 2020, 95, 376–383. [CrossRef] [PubMed]

55. Savasi, V.M.; Parisi, F.; Patanè, L.; Ferrazzi, E.; Frigerio, L.; Pellegrino, A.; Spinillo, A.; Tateo, S.; Ottoboni, M.; Veronese, P.; et al. Clinical Findings and Disease Severity in Hospitalized Pregnant Women with Coronavirus Disease 2019 (COVID-19). *Obstet. Gynecol.* 2020, 136, 252–258. [CrossRef] [PubMed]

56. Sentilhes, L.; De Marcillac, F.; Jouffrieau, C.; Kuhn, P.; Thuet, V.; Hansmann, Y.; Ruch, Y.; Fafi-Kremer, S.; Deruelle, P. COVID-19 in pregnancy was associated with maternal morbidity and preterm birth. *Am. J. Obstet. Gynecol. MFM* 2020. [CrossRef]

57. Siying, Z.; Juanjuan, G.; Yuming, C.; Huijun, C.; Dan, X.; Jiafu, L.; Yuanzhen, Z. A case of new coronavirus infection in perinatal period. *Clin. J. Perinat. Med.* 2020, 23, 85–90.

58. Wang, S.; Guo, L.; Chen, L.; Liu, W.; Cao, Y.; Zhang, J.; Feng, L. A case report of neonatal COVID-19 infection in China. *Clin. Infect. Dis.* 2020, 71, 853–857. [CrossRef]
59. Wang, X.; Zhou, Z.; Zhang, J.; Zhu, F.; Tang, Y.; Shen, X. A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery. *Clin. Infect. Dis.* 2020, 71, 844–846. [CrossRef]

60. Wu, X.; Sun, R.; Chen, J.; Xie, Y.; Zhang, S.; Wang, X. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia. *Int. J. Gynaecol. Obstet.* 2020. [CrossRef]

61. Wu, Y.; Liu, C.; Dong, L.; Zhang, C.; Chen, Y.; Liu, J.; Zhang, C.; Duan, C.; Zhang, H.; Mol, B.W.; et al. Coronavirus disease 2019 among pregnant Chinese women: Case series data on the safety of vaginal birth and breastfeeding. *BJOG* 2020, 127, 1109–1115. [CrossRef]

62. Xiong, X.; Wei, H.; Zhang, Z.; Chang, J.; Ma, X.; Gao, X.; Chen, Q.; Pang, Q. Vaginal Delivery Report of a Healthy Neonate Born to a Convalescent Mother with COVID-19. *J. Med. Virol.* 2020, 92, 1657–1659. [CrossRef] [PubMed]

63. Yan, J.; Guo, J.; Fan, C.; Yuan, J.; Yu, X.; Li, J.; Peng, L.; Li, C.; Chen, H.; Qiao, Y.; et al. Coronavirus disease 2019 in pregnant women: A report based on 116 cases. *Am. J. Obstet. Gynecol. MFM* 2020. [CrossRef] [PubMed]

64. Yang, H.; Hu, B.; Zhan, S.; Yang, L.Y.; Xiong, G. Effects of SARS-CoV-2 infection on pregnant women and their infants: A retrospective study in Wuhan, China. *Arch. Pathol. Lab. Med.* 2020. [CrossRef] [PubMed]

65. Yang, P.; Wang, X.; Liu, P.; Wei, C.; He, B.; Zheng, J.; Zhao, D. Clinical characteristics and risk assessment of newborns born to mothers with COVID-19. *J. Clin. Virol.* 2020, 127, 104356. [CrossRef] [PubMed]

66. Yu, N.; Li, W.; Kang, Q.; Xiong, Z.; Wang, S.; Lin, X.; Liu, Y.; Xiao, J.; Liu, H.; Deng, D.; et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: A retrospective, single-centre, descriptive study. *Lancet Infect. Dis.* 2020. [CrossRef]

67. Yu, Y.; Fan, C.; Bian, J.; Shen, Y. Severe COVID-19 in a pregnant patient admitted to hospital in Wuhan. *Int. J. Gynecol. Obstet.* 2020, 150, 262–263. [CrossRef]

68. Zeng, L.; Xia, S.; Yuan, W.; Yan, K.; Xiao, F.; Shao, J.; Zhou, W. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr.* 2020, 174, 722. [CrossRef]

69. Zhang, L.; Jiang, Y.; Wei, M.; Cheng, B.H.; Zhou, X.C.; Li, J.; Tian, J.H.; Dong, L.; Hu, R.H. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province. *Zhonghua Fu Chan Ke Za Zhi* 2020, 55, E009.

70. Zhu, H.; Wang, L.; Fang, C.; Peng, S.; Zhang, L.; Chang, G.; Xia, S.; Zhou, W. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl. Pediatrics* 2020, 9, 51–60. [CrossRef]

71. Lowe, B.; Bopp, B. COVID-19 vaginal delivery—A case report. *Aust. N. Z. J. Obstet. Gynaecol.* 2020, 60, 465–466. [CrossRef]

72. Hijona Elósegui, J.J.; Carballo García, A.L.; Fernández Rizquez, A.C.; Bermúdez Quintana, M.; Expósito Montes, J.F. Does the maternal-fetal transmission of SARS-CoV-2 occur during pregnancy? *Rev. Clin. Esp.* 2020. [CrossRef] [PubMed]

73. Yue, L.; Han, L.; Li, Q.; Zhong, M.; Wang, J.; Wan, Z.; Chu, C.; Zeng, Y.; Peng, M.; Yang, L.; et al. Anaesthesia and infection control in caesarean section of pregnant women with coronavirus disease 2019 (COVID-19). *medRxiv* 2020. [CrossRef]

74. Vivanti, A.J.; Vauloup-Fellous, C.; Prevot, S.; Zupan, V.; Suffee, C.; Do Cao, J.; Benachi, A.; De Luca, D. Transplacental transmission of SARS-CoV-2 infection. *Nat. Commun.* 2020, 11, 3572. [CrossRef] [PubMed]

75. Sisman, J.; Jaleel, M.A.; Moreno, W.; Rajaram, V.; Collins, R.R.J.; Savani, R.C.; Rakheja, D.; Evans, A.S. Intrauterine Transmission of SARS-COV-2 Infection in a Preterm Infant. *Pediatric Infect. Dis. J.* 2020, 39, e265–e267. [CrossRef] [PubMed]

76. Schwartz, D.A.; Mohagheghi, P.; Beigi, B.; Zafaranloo, N.; Moshfegh, F.; Yazdani, A. Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes. *J. Matern.-Fetal Neonatal Med.* 2020, 1–10. [CrossRef]

77. Pereira, A.; Cruz-Melguizo, S.; Adrien, M.; Fuentes, L.; Marin, E.; Perez-Medina, T. Clinical course of coronavirus disease-2019 in pregnancy. *Acta Obstet. Et Gynecol. Scand.* 2020, 99, 839–847. [CrossRef]

78. Ly, Y.; Gu, B.; Chen, Y.; Hu, S.; Ruan, T.; Xu, G.; Ding, J.; Xu, X.; Shen, X. No intrauterine vertical transmission in pregnancy with COVID-19: A case report. *J. Infect. Chemother.* 2020, 26, 1313–1315. [CrossRef]

79. Hosier, H.; Farhadian, S.F.; Morotti, R.A.; Deshmukh, U.; Lu-Culligan, A.; Campbell, K.H.; Yasumoto, Y.; Vogels, C.B.; Casanovas-Massana, A.; Vijayakumar, P.; et al. SARS-CoV-2 infection of the placenta. *J. Clin. Investig.* 2020, 130, 4947–4953. [CrossRef]
80. Marin Gabriel, M.; Malalana Martínez, A.M.; Marín Martínez, M.E.; Anel Pedroche, J. Negative Transmission of SARS-CoV-2 to Hand-Expressed Colostrum from SARS-CoV-2-Positive Mothers. *Breastfeed. Med.* 2020, 15, 492–494. [CrossRef]

81. Ferraiolo, A.; Barra, F.; Kratochvila, C.; Paudice, M.; Vellone, V.G.; Godano, E.; Varesano, S.; Noberasco, G.; Ferrero, S.; Arioni, C. Report of Positive Placental Swabs for SARS-CoV-2 in an Asymptomatic Pregnant Woman with COVID-19. *Medicina* 2020, 56, 306. [CrossRef]

82. Fenizia, C.; Biasin, M.; Getin, I.; Vergani, P.; Mileto, D.; Spinillo, A.; Gismondo, M.R.; Perotti, F.; Callegari, C.; Mancon, A.; et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy. *Nat. Commun.* 2020, 11, 5128. [CrossRef] [PubMed]

83. Facchetti, F.; Bugatti, M.; Drera, E.; Tripodo, C.; Sartori, E.; Cancila, V.; Papaccio, M.; Castellani, R.; Casola, S.; Boniotti, M.B.; et al. SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. *EBioMedicine* 2020, 59. [CrossRef]

84. Costa, S.; Posteraro, B.; Marchetti, S.; Tamburrini, E.; Carducci, B.; Lanzone, A.; Valentini, P.; Buonsenso, D.; Sanguinetti, M.; Vento, G.; et al. Excretion of SARS-CoV-2 in human breast milk. *Clin. Microbiol. Infect.* 2020, 26, 1430–1432. [CrossRef] [PubMed]

85. Algarroba, G.N.; Rekawek, P.; Vahanian, S.A.; Khullar, P.; Palaia, T.; Peltier, M.R.; Chavez, M.R.; Vintzileos, A.M. Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy. *Am. J. Obstet. Gynecol. MFM* 2020, 223, 275–278. [CrossRef] [PubMed] [CrossRef] [PubMed]

86. Zeng, Y.; Lin, L.; Yan, Q.; Wei, W.; Yang, B.X.; Huang, R.; He, F.; Chen, D. Update on clinical outcomes of women with COVID-19 during pregnancy. *Int. J. Gynaecol. Obstet.* 2020, 150, 264–266. [CrossRef]

87. Wang, S.; Li, M.; Ye, Z.; Yang, C.; Cai, Q.; Duan, S.; Song, B. CT Manifestations and Clinical Characteristics of 1115 Patients with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis. *Acad. Radiol.* 2020, 27, 910–921. [CrossRef]

88. Celik, O.; Saglam, A.; Baysal, B.; Derwig, I.E.; Celik, N.; Ak, M.; Aslan, S.N.; Ulas, M.; Ersahin, A.; Tayyar, A.T.; et al. Factors preventing materno-fetal transmission of SARS-CoV-2. *Placenta* 2020, 97, 1–5. [CrossRef] [PubMed]

89. Mahyuddin, A.P.; Kanneganti, A.; Wong, J.; Dimri, P.S.; Su, L.L.; Biswas, A.; Illanes, S.E.; Mattar, C.; Huang, R.-J.; Choolani, M. Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2. *Prenat. Diagn* 2020. [CrossRef]

90. Dashraath, P.; Wong, J.L.J.; Lim, M.X.K.; Lim, L.M.; Li, S.; Biswas, A.; Choolani, M.; Mattar, C.; Su, L.L. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am. J. Obstet. Gynecol. MFM* 2020, 222, 521–531. [CrossRef] [PubMed]

91. Rasmussen, S.A.; Jamieson, D.J. Caring for Women Who Are Planning a Pregnancy, Pregnant, or Postpartum During the COVID-19 Pandemic. *JAMA* 2020, 324, 190. [CrossRef]

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).